Details of the Drug Combination

General Information of Drug Combination (ID: DCWGHF4)

Drug Combination Name
Indomethacin Tacrolimus
Indication
Disease Entry Status REF
Post-ERCP Acute Pancreatitis Phase 3 [1]
Component Drugs Indomethacin   DMSC4A7 Tacrolimus   DMZ7XNQ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Indomethacin
Disease Entry ICD 11 Status REF
Bursitis N.A. Approved [2]
Gout FA25 Approved [2]
Osteoarthritis FA00-FA05 Approved [2]
Patent ductus arteriosus N.A. Approved [2]
Rheumatic disorder N.A. Approved [2]
Rheumatoid arthritis FA20 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1/2 [4]
Synovitis N.A. Investigative [2]
Indomethacin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Modulator [18]
------------------------------------------------------------------------------------
Indomethacin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [19]
------------------------------------------------------------------------------------
Indomethacin Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [20]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [20]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [20]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [21]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [21]
------------------------------------------------------------------------------------
Indomethacin Interacts with 315 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [22]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Phosphorylation [23]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Increases Expression [24]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [25]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Expression [26]
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Increases Expression [27]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Increases ADR [28]
Plasma kallikrein (KLKB1) OTGSEISX KLKB1_HUMAN Increases ADR [28]
B2 bradykinin receptor (BDKRB2) OTOA9D3W BKRB2_HUMAN Increases ADR [28]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Decreases Activity [29]
Carbonic anhydrase 1 (CA1) OTNFBVVQ CAH1_HUMAN Increases Activity [30]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Increases Activity [30]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Decreases Activity [31]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Decreases Activity [31]
Solute carrier family 22 member 6 (SLC22A6) OTKRCBVM S22A6_HUMAN Decreases Activity [31]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Decreases Activity [31]
Solute carrier family 22 member 11 (SLC22A11) OTAJLNJZ S22AB_HUMAN Decreases Activity [31]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Decreases Activity [31]
Aldo-keto reductase family 1 member C4 (AKR1C4) OTW2MMOF AK1C4_HUMAN Decreases Activity [32]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Decreases Activity [32]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Decreases Activity [32]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [33]
Prostaglandin G/H synthase 1 (PTGS1) OTHCRLEC PGH1_HUMAN Decreases Activity [34]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [35]
Importin-5 (IPO5) OTAK40ED IPO5_HUMAN Decreases Expression [10]
Transcription factor E2F3 (E2F3) OT5VQMWY E2F3_HUMAN Decreases Expression [10]
AT-rich interactive domain-containing protein 1A (ARID1A) OTRWDV3P ARI1A_HUMAN Decreases Expression [10]
Class E basic helix-loop-helix protein 40 (BHLHE40) OTITX14U BHE40_HUMAN Increases Expression [10]
Chromodomain-helicase-DNA-binding protein 1 (CHD1) OT9R9G0H CHD1_HUMAN Decreases Expression [10]
Mothers against decapentaplegic homolog 7 (SMAD7) OTSLHWF4 SMAD7_HUMAN Increases Expression [10]
E3 ubiquitin-protein ligase Praja-2 (PJA2) OT45TMC4 PJA2_HUMAN Decreases Expression [10]
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Increases Expression [10]
Phospholipid-transporting ATPase IC (ATP8B1) OTALGS63 AT8B1_HUMAN Decreases Expression [10]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Increases Expression [10]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Increases Expression [10]
cAMP-responsive element-binding protein-like 2 (CREBL2) OT58JBNU CRBL2_HUMAN Decreases Expression [10]
Thiamine transporter 1 (SLC19A2) OTH5SB0M S19A2_HUMAN Increases Expression [10]
DnaJ homolog subfamily A member 2 (DNAJA2) OTKF1VBT DNJA2_HUMAN Decreases Expression [10]
Frizzled-7 (FZD7) OTTK3F6E FZD7_HUMAN Decreases Expression [10]
Rho-associated protein kinase 2 (ROCK2) OTVYN14T ROCK2_HUMAN Decreases Expression [10]
Suppressor of cytokine signaling 5 (SOCS5) OTN1ABYR SOCS5_HUMAN Decreases Expression [10]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B) OTL9I7LO GA45B_HUMAN Increases Expression [10]
Glutaminase kidney isoform, mitochondrial (GLS) OTGOZG2M GLSK_HUMAN Decreases Expression [10]
Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) OTBMJUOC M4K4_HUMAN Decreases Expression [10]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [10]
Beta-nerve growth factor (NGF) OTOLABJT NGF_HUMAN Increases Expression [10]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Decreases Expression [10]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Increases Expression [10]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Increases Expression [10]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Increases Expression [10]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [10]
Thrombomodulin (THBD) OT8VHLKY TRBM_HUMAN Decreases Expression [10]
Tyrosine-protein kinase Lyn (LYN) OTP686K2 LYN_HUMAN Decreases Expression [10]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Expression [10]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [10]
RNA-binding protein RO60 (RO60) OTLGM5A8 RO60_HUMAN Decreases Expression [10]
Interleukin-7 (IL7) OTT6YSKM IL7_HUMAN Decreases Expression [10]
Transcription factor JunB (JUNB) OTG2JXV5 JUNB_HUMAN Increases Expression [10]
S-adenosylmethionine decarboxylase proenzyme (AMD1) OTKAGZY3 DCAM_HUMAN Decreases Expression [10]
Protein SON (SON) OT9VWV18 SON_HUMAN Decreases Expression [10]
Interleukin-11 (IL11) OTXHN86R IL11_HUMAN Increases Expression [10]
COUP transcription factor 2 (NR2F2) OTJFS67N COT2_HUMAN Decreases Expression [10]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Increases Expression [10]
Guanylate-binding protein 1 (GBP1) OTUM7RPJ GBP1_HUMAN Decreases Expression [10]
Transcription factor SOX-18 (SOX18) OTPUMHWA SOX18_HUMAN Increases Expression [10]
Interleukin-6 receptor subunit beta (IL6ST) OT1N9C70 IL6RB_HUMAN Decreases Expression [10]
Protein kinase C iota type (PRKCI) OTKBAVT3 KPCI_HUMAN Decreases Expression [10]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Decreases Expression [10]
Eukaryotic translation initiation factor 1A, X-chromosomal (EIF1AX) OTWG2LAB IF1AX_HUMAN Decreases Expression [10]
Protein Tob1 (TOB1) OTNW949D TOB1_HUMAN Decreases Expression [10]
Monocarboxylate transporter 1 (SLC16A1) OTW1UTZ7 MOT1_HUMAN Decreases Expression [10]
UV excision repair protein RAD23 homolog B (RAD23B) OT0PGOG3 RD23B_HUMAN Decreases Expression [10]
ATP synthase subunit e, mitochondrial (ATP5ME) OTADVEE2 ATP5I_HUMAN Increases Expression [10]
ADP-ribosylation factor-like protein 4C (ARL4C) OTQ3QNNU ARL4C_HUMAN Decreases Expression [10]
Protein BTG1 (BTG1) OTVJ2CDM BTG1_HUMAN Increases Expression [10]
Rho-related GTP-binding protein RhoB (RHOB) OTHQFQF7 RHOB_HUMAN Increases Expression [10]
Dystonin (DST) OTHZBM4X DYST_HUMAN Decreases Expression [10]
Tyrosine-protein phosphatase non-receptor type 12 (PTPN12) OT5WA666 PTN12_HUMAN Decreases Expression [10]
Serine/arginine-rich splicing factor 6 (SRSF6) OTGLOSYE SRSF6_HUMAN Decreases Expression [10]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [10]
Serine/threonine-protein kinase PRP4 homolog (PRP4K) OT4C7XNK PRP4B_HUMAN Decreases Expression [10]
G/T mismatch-specific thymine DNA glycosylase (TDG) OTJB0YIH TDG_HUMAN Decreases Expression [10]
Protein EFR3 homolog A (EFR3A) OTVHT160 EFR3A_HUMAN Decreases Expression [10]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Increases Expression [10]
AT-rich interactive domain-containing protein 5B (ARID5B) OTUQ4CQY ARI5B_HUMAN Decreases Expression [10]
TSC22 domain family protein 1 (TSC22D1) OTN4GFWD T22D1_HUMAN Increases Expression [10]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [10]
Cleavage and polyadenylation specificity factor subunit 6 (CPSF6) OTM6QYNQ CPSF6_HUMAN Decreases Expression [10]
Dual specificity protein phosphatase 6 (DUSP6) OT4H6RKW DUS6_HUMAN Decreases Expression [10]
Tumor protein D53 (TPD52L1) OTSA6U0I TPD53_HUMAN Decreases Expression [10]
Centrosome and spindle pole-associated protein 1 (CSPP1) OTNX7GD4 CSPP1_HUMAN Decreases Expression [10]
Protein LBH (LBH) OT87AT1X LBH_HUMAN Increases Expression [10]
NHS-like protein 1 (NHSL1) OTLEZ2C3 NHSL1_HUMAN Decreases Expression [10]
Putative uncharacterized protein C6orf52 (C6ORF52) OTDW07T3 CF052_HUMAN Increases Expression [10]
PX domain-containing protein 1 (PXDC1) OTQUA3TG PXDC1_HUMAN Increases Expression [10]
Zinc finger protein AEBP2 (AEBP2) OTOAZJ55 AEBP2_HUMAN Decreases Expression [10]
Ras-associated and pleckstrin homology domains-containing protein 1 (RAPH1) OTMQXW7S RAPH1_HUMAN Decreases Expression [10]
FMR1-interacting protein NUFIP2 (NUFIP2) OTZBZ224 NUFP2_HUMAN Decreases Expression [10]
E3 ubiquitin-protein ligase RNF144B (RNF144B) OTN7FCDE R144B_HUMAN Decreases Expression [10]
Neuroepithelial cell-transforming gene 1 protein (NET1) OTZHNMJV ARHG8_HUMAN Increases Expression [10]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Increases Expression [10]
Histone-arginine methyltransferase METTL23 (METTL23) OTO7O557 MET23_HUMAN Increases Expression [10]
Protein O-mannosyl-transferase TMTC1 (TMTC1) OTZ7NW96 TMTC1_HUMAN Decreases Expression [10]
Coiled-coil domain-containing protein 50 (CCDC50) OTSE1YM5 CCD50_HUMAN Increases Expression [10]
E3 ubiquitin-protein ligase HACE1 (HACE1) OTEZULKD HACE1_HUMAN Decreases Expression [10]
Ankyrin repeat domain-containing protein 13C (ANKRD13C) OT8LJ550 AN13C_HUMAN Decreases Expression [10]
Hemicentin-2 (HMCN2) OTJK9CGG HMCN2_HUMAN Increases Expression [10]
Acrosin-binding protein (ACRBP) OT0MK3L1 ACRBP_HUMAN Increases Expression [10]
Mitochondria-eating protein (SPATA18) OTOEHTHU MIEAP_HUMAN Decreases Expression [10]
Pantothenate kinase 1 (PANK1) OT2CZVRT PANK1_HUMAN Decreases Expression [10]
Rap guanine nucleotide exchange factor 6 (RAPGEF6) OTR1QQA3 RPGF6_HUMAN Decreases Expression [10]
Neuronal cell adhesion molecule (NRCAM) OT80HHQ2 NRCAM_HUMAN Decreases Expression [10]
Transcription factor GATA-6 (GATA6) OTO2BC0F GATA6_HUMAN Increases Expression [10]
Protein TMEPAI (PMEPA1) OTY8Z9UF PMEPA_HUMAN Increases Expression [10]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Increases Expression [10]
BTB/POZ domain-containing protein KCTD12 (KCTD12) OTPYKT4Z KCD12_HUMAN Decreases Expression [10]
RING finger protein 145 (RNF145) OTBCTG4A RN145_HUMAN Decreases Expression [10]
Transmembrane protein 237 (TMEM237) OTQEVL7L TM237_HUMAN Decreases Expression [10]
Trimethylguanosine synthase (TGS1) OTM79LML TGS1_HUMAN Decreases Expression [10]
RNA-binding protein 15 (RBM15) OT8ZPGWF RBM15_HUMAN Decreases Expression [10]
Plakophilin-4 (PKP4) OTQHOF8L PKP4_HUMAN Decreases Expression [10]
Homeobox protein Nkx-3.1 (NKX3-1) OT0DO6ZU NKX31_HUMAN Increases Expression [10]
Cbp/p300-interacting transactivator 2 (CITED2) OT812TV7 CITE2_HUMAN Decreases Expression [10]
Transcription factor SOX-7 (SOX7) OTOZOFAG SOX7_HUMAN Decreases Expression [10]
Death-inducer obliterator 1 (DIDO1) OT9PB547 DIDO1_HUMAN Decreases Expression [10]
Angiopoietin-related protein 4 (ANGPTL4) OTQL5SPX ANGL4_HUMAN Increases Expression [10]
Forkhead box protein Q1 (FOXQ1) OT6S3EB0 FOXQ1_HUMAN Increases Expression [10]
Activity-dependent neuroprotector homeobox protein (ADNP) OTEGICWR ADNP_HUMAN Decreases Expression [10]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) OT3Q11WQ I20L2_HUMAN Decreases Expression [10]
Retroelement silencing factor 1 (RESF1) OTQIZIJF RESF1_HUMAN Decreases Expression [10]
DnaJ homolog subfamily C member 4 (DNAJC4) OT4BUBQU DNJC4_HUMAN Increases Expression [10]
Muscleblind-like protein 1 (MBNL1) OTOV7J85 MBNL1_HUMAN Decreases Expression [10]
Bromodomain adjacent to zinc finger domain protein 1A (BAZ1A) OTWHOVZS BAZ1A_HUMAN Decreases Expression [10]
Sperm protein associated with the nucleus on the X chromosome A (SPANXA1) OTMK3QIS SPNXA_HUMAN Increases Expression [10]
Sal-like protein 1 (SALL1) OTYYZGLH SALL1_HUMAN Increases Expression [10]
BMP-2-inducible protein kinase (BMP2K) OT0IRJBY BMP2K_HUMAN Decreases Expression [10]
Serine/threonine-protein phosphatase 4 regulatory subunit 2 (PPP4R2) OT7FCZRM PP4R2_HUMAN Decreases Expression [10]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Decreases Expression [10]
]-phosphatase 1, mitochondrial (PDP1) OT82RTMT PDP1_HUMAN Decreases Expression [10]
DNA repair protein REV1 (REV1) OTHIKICX REV1_HUMAN Decreases Expression [10]
Translocation protein SEC63 homolog (SEC63) OT1ICPMK SEC63_HUMAN Decreases Expression [10]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Decreases Expression [10]
Tomoregulin-2 (TMEFF2) OT1WZ2QO TEFF2_HUMAN Decreases Expression [10]
F-box/WD repeat-containing protein 2 (FBXW2) OTCHPUCP FBXW2_HUMAN Decreases Expression [10]
Scrapie-responsive protein 1 (SCRG1) OTBE7V0P SCRG1_HUMAN Increases Expression [11]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [11]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [11]
Glutamine synthetase (GLUL) OTYGTCGF GLNA_HUMAN Decreases Expression [11]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Increases Expression [11]
Cystathionine beta-synthase (CBS) OT46FSKD CBS_HUMAN Increases Expression [11]
Serine--tRNA ligase, cytoplasmic (SARS1) OTFKXQ1O SYSC_HUMAN Increases Expression [11]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Decreases Expression [11]
Phosphoserine phosphatase (PSPH) OTV1PVAX SERB_HUMAN Increases Expression [11]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Increases Expression [11]
Methylsterol monooxygenase 1 (MSMO1) OTKV62RZ MSMO1_HUMAN Increases Expression [11]
Mitochondrial 10-formyltetrahydrofolate dehydrogenase (ALDH1L2) OTCH86VF AL1L2_HUMAN Increases Expression [11]
Spermatogenesis-associated serine-rich protein 1 (SPATS1) OTPUXCSA SPAS1_HUMAN Decreases Expression [11]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Increases Expression [11]
Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) OTJGE772 CHAC1_HUMAN Increases Expression [11]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Decreases Expression [11]
Cell cycle progression protein 1 (CCPG1) OT0IHDKL CCPG1_HUMAN Increases Expression [11]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [11]
Adenosine receptor A3 (ADORA3) OTHO1BLK AA3R_HUMAN Increases Expression [36]
5'-nucleotidase (NT5E) OT7J5LT6 5NTD_HUMAN Increases Expression [36]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Decreases Activity [37]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [38]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [39]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [39]
Leukocyte cell-derived chemotaxin 1 (CNMD) OTHND8EL CNMD_HUMAN Increases Expression [13]
ABC-type organic anion transporter ABCA8 (ABCA8) OTCWLX6N ABCA8_HUMAN Increases Expression [13]
RAS guanyl-releasing protein 1 (RASGRP1) OTX9WN2E GRP1_HUMAN Increases Expression [13]
C-X-C motif chemokine 14 (CXCL14) OTM189TA CXL14_HUMAN Increases Expression [13]
Collagen alpha-1(II) chain (COL2A1) OT5E59C8 CO2A1_HUMAN Decreases Expression [13]
Homeobox protein Hox-D4 (HOXD4) OTQR4WCG HXD4_HUMAN Decreases Expression [13]
Homeobox protein Hox-D3 (HOXD3) OTBUZ35T HXD3_HUMAN Decreases Expression [13]
Metalloproteinase inhibitor 3 (TIMP3) OTDGQAD1 TIMP3_HUMAN Increases Expression [13]
Nuclear receptor subfamily 4 group A member 2 (NR4A2) OT3F9IR2 NR4A2_HUMAN Decreases Expression [13]
Excitatory amino acid transporter 4 (SLC1A6) OTRSPH8U EAA4_HUMAN Increases Expression [13]
LIM/homeobox protein Lhx1 (LHX1) OT6WI2XS LHX1_HUMAN Decreases Expression [13]
Ras association domain-containing protein 2 (RASSF2) OT2JHDO4 RASF2_HUMAN Increases Expression [13]
Paired mesoderm homeobox protein 1 (PRRX1) OTTZK5G8 PRRX1_HUMAN Decreases Expression [13]
Protein delta homolog 1 (DLK1) OTE1VLNB DLK1_HUMAN Increases Expression [13]
Runt-related transcription factor 1 (RUNX1) OTU7J84H RUNX1_HUMAN Increases Expression [13]
Myosin light chain kinase, smooth muscle (MYLK) OT78QB4A MYLK_HUMAN Increases Expression [13]
Growth/differentiation factor 6 (GDF6) OTERXWJU GDF6_HUMAN Increases Expression [13]
Epidermal growth factor-like protein 6 (EGFL6) OT331X59 EGFL6_HUMAN Increases Expression [13]
Rhomboid-related protein 4 (RHBDD1) OTL5J132 RHBL4_HUMAN Increases Expression [13]
SOSS complex subunit B2 (NABP1) OTFTNFHW SOSB2_HUMAN Increases Expression [13]
Ribosomal protein eL39-like 2 (RPL39L) OTAV1MJQ RL39L_HUMAN Increases Expression [13]
Homeobox protein Hox-D1 (HOXD1) OTN4V9ZF HXD1_HUMAN Decreases Expression [13]
Band 4.1-like protein 4B (EPB41L4B) OT2K30P7 E41LB_HUMAN Increases Expression [13]
Regulator of cell cycle RGCC (RGCC) OTYJMLWM RGCC_HUMAN Increases Expression [13]
Homeobox protein NANOG (NANOG) OTUEY1FM NANOG_HUMAN Decreases Expression [13]
Armadillo repeat-containing X-linked protein 1 (ARMCX1) OTOGL58Z ARMX1_HUMAN Decreases Expression [13]
Dickkopf-related protein 2 (DKK2) OTKSZSUM DKK2_HUMAN Increases Expression [13]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Increases Expression [13]
Nuclear factor erythroid 2-related factor 3 (NFE2L3) OT1MGXT0 NF2L3_HUMAN Increases Expression [13]
Calpain-6 (CAPN6) OT8K5PR5 CAN6_HUMAN Increases Expression [13]
Prostaglandin reductase 1 (PTGR1) OTMAR351 PTGR1_HUMAN Decreases Activity [40]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [41]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [42]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [43]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [44]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Increases Expression [27]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [41]
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21) OT3EDGXO TNR21_HUMAN Decreases Expression [45]
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Decreases Activity [46]
CCN family member 4 (CCN4) OT69BER9 CCN4_HUMAN Decreases Expression [47]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [27]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Activity [48]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [49]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Increases Expression [50]
Kininogen-1 (KNG1) OT4X9LDE KNG1_HUMAN Decreases Activity [51]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [52]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Increases Expression [53]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Decreases Expression [54]
Vasopressin-neurophysin 2-copeptin (AVP) OTAVZ76K NEU2_HUMAN Decreases Secretion [55]
Insulin (INS) OTZ85PDU INS_HUMAN Decreases Secretion [56]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [27]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Expression [41]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Secretion [41]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [27]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Affects Cleavage [57]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Secretion [58]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [59]
Protein kinase C beta type (PRKCB) OTYQ0656 KPCB_HUMAN Decreases Expression [60]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Expression [61]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases Expression [27]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Decreases Expression [41]
Cathepsin B (CTSB) OTP9G5QB CATB_HUMAN Decreases Activity [62]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [27]
Annexin A5 (ANXA5) OTZS877V ANXA5_HUMAN Increases Expression [63]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [27]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [64]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [65]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [66]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [41]
Laminin subunit gamma-1 (LAMC1) OTIG527N LAMC1_HUMAN Decreases Expression [67]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Affects Localization [68]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [69]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [47]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [70]
L-selectin (SELL) OT6RAJZR LYAM1_HUMAN Decreases Expression [24]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [71]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Increases Expression [72]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Increases Expression [73]
Nucleoside diphosphate kinase A (NME1) OT0NELQ1 NDKA_HUMAN Increases Expression [74]
Platelet glycoprotein 4 (CD36) OT5CZWKY CD36_HUMAN Increases Expression [41]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [75]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Secretion [76]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Increases Expression [41]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Expression [27]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Secretion [58]
Nuclear receptor subfamily 4immunitygroup A member 1 (NR4A1) OTGP6GA4 NR4A1_HUMAN Increases Expression [77]
Protein kinase C eta type (PRKCH) OTC498N5 KPCL_HUMAN Increases Expression [60]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Activity [78]
Adenomatous polyposis coli protein (APC) OTKV0TIK APC_HUMAN Increases Expression [70]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [79]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [80]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [81]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [22]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [41]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Increases Expression [82]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Activity [78]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Decreases Expression [83]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [22]
Prostaglandin E2 receptor EP2 subtype (PTGER2) OT1AUZAA PE2R2_HUMAN Decreases Expression [84]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Increases Expression [85]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Increases Expression [86]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Increases Expression [86]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [41]
C-C chemokine receptor type 3 (CCR3) OT6GBUFA CCR3_HUMAN Decreases Expression [24]
ATP-citrate synthase (ACLY) OTRL9ZRP ACLY_HUMAN Increases Expression [41]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [41]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Expression [27]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [87]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [88]
Thymosin beta-4 (TMSB4X) OT9HPLP3 TYB4_HUMAN Increases Expression [89]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [90]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [91]
Protein kinase C epsilon type (PRKCE) OT7J0P9L KPCE_HUMAN Increases Expression [60]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Affects Activity [92]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Increases Expression [93]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Affects Localization [94]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Decreases Phosphorylation [95]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Decreases Expression [96]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [27]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [97]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Increases Expression [93]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Expression [41]
Transcription factor HES-1 (HES1) OT8P19W2 HES1_HUMAN Decreases Expression [22]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Localization [86]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [47]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [64]
Occludin (OCLN) OTSUTVWL OCLN_HUMAN Decreases Expression [96]
Dehydrogenase/reductase SDR family member 11 (DHRS11) OTU3J0ZL DHR11_HUMAN Decreases Activity [98]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Activity [99]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [22]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [22]
Perilipin-2 (PLIN2) OTRXJ9UN PLIN2_HUMAN Increases Expression [93]
Phospholipid-transporting ATPase ABCA3 (ABCA3) OTH6MSKQ ABCA3_HUMAN Decreases Expression [26]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [75]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Expression [41]
Angiopoietin-related protein 3 (ANGPTL3) OTCD5Z9W ANGL3_HUMAN Decreases Expression [41]
Prostaglandin D2 receptor 2 (PTGDR2) OTCSMVF1 PD2R2_HUMAN Increases Activity [100]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Increases ADR [28]
Cytochrome b5 (CYB5A) OT6SN4RM CYB5_HUMAN Increases ADR [28]
Alpha-1-antitrypsin (SERPINA1) OTACYW9J A1AT_HUMAN Increases Response To Substance [101]
Epoxide hydrolase 1 (EPHX1) OTBKWQER HYEP_HUMAN Increases ADR [28]
Heat shock 70 kDa protein 12A (HSPA12A) OTFOCDD6 HS12A_HUMAN Increases ADR [28]
p21 protein (HRAS) OTFYE6AJ P78460_HUMAN Increases ADR [28]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases ADR [28]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases ADR [28]
NADH-cytochrome b5 reductase 3 (CYB5R3) OTUGT3G8 NB5R3_HUMAN Increases ADR [28]
P-selectin (SELP) OTWR90PK LYAM3_HUMAN Increases ADR [28]
------------------------------------------------------------------------------------
⏷ Show the Full List of 315 DOT(s)
Indication(s) of Tacrolimus
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Approved [5]
Hepatosplenic T-cell lymphoma N.A. Approved [5]
Kidney transplant rejection NE84 Approved [5]
Large granular lymphocytic leukemia 2A90.1 Approved [5]
Leukemia N.A. Approved [5]
Lupus nephritis 4A40.0Y Approved [5]
MALT lymphoma N.A. Approved [5]
Myeloproliferative neoplasm 2A20 Approved [5]
Nodal marginal zone lymphoma 2A85.0 Approved [5]
Organ transplant rejection NE84 Approved [6]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [5]
Recurrent adult burkitt lymphoma 2A85.6 Approved [5]
Small intestine lymphoma N.A. Approved [5]
Splenic marginal zone lymphoma N.A. Approved [5]
Testicular lymphoma N.A. Approved [5]
Ocular allergy 4A81 Phase 3 [6]
Classic Hodgkin lymphoma N.A. Investigative [5]
Tacrolimus Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Calcineurin (PPP3CA) TTA4LDE PP2BA_HUMAN Inhibitor [104]
------------------------------------------------------------------------------------
Tacrolimus Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [105]
------------------------------------------------------------------------------------
Tacrolimus Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [106]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [107]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Metabolism [108]
Ribosomal 23S RNA methyltransferase Erm (erm) DEW6V07 A0A5N1AHF6_CORAY Metabolism [109]
Ribosomal 23S RNA methyltransferase Erm (erm) DEA65D8 A0A381KDL2_CORJE Metabolism [109]
------------------------------------------------------------------------------------
Tacrolimus Interacts with 49 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Methylation [110]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Methylation [110]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Affects Response To Substance [111]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Response To Substance [112]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [113]
Cytochrome b-245 light chain (CYBA) OT16N9ZO CY24A_HUMAN Increases Expression [113]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Expression [113]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [114]
Natural cytotoxicity triggering receptor 3 (NCR3) OT20M764 NCTR3_HUMAN Increases Expression [115]
Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) OTCYYCAC HGS_HUMAN Increases Expression [103]
Rho guanine nucleotide exchange factor 11 (ARHGEF11) OTDOMEH6 ARHGB_HUMAN Increases Expression [103]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [116]
Actin-related protein 2/3 complex subunit 5 (ARPC5) OTFNMMDL ARPC5_HUMAN Increases Expression [103]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Decreases Expression [116]
Zinc finger protein SNAI1 (SNAI1) OTDPYAMC SNAI1_HUMAN Increases Expression [102]
Insulin (INS) OTZ85PDU INS_HUMAN Decreases Expression [117]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Secretion [118]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [119]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [120]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [121]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Increases Expression [121]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Expression [119]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [119]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [122]
Interleukin-3 (IL3) OT0CQ35N IL3_HUMAN Decreases Expression [119]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [123]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Decreases Expression [102]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Decreases Expression [122]
Ras-related protein Rab-4A (RAB4A) OT7BL9WW RAB4A_HUMAN Increases Expression [103]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Decreases Degradation [118]
T-lymphocyte activation antigen CD80 (CD80) OTJBLUQE CD80_HUMAN Decreases Expression [124]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [124]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Cleavage [125]
Troponin T, cardiac muscle (TNNT2) OT80NN7R TNNT2_HUMAN Increases Expression [126]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Decreases Secretion [127]
Glycogen synthase kinase-3 alpha (GSK3A) OT0F6DWV GSK3A_HUMAN Increases Phosphorylation [102]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [102]
Eotaxin (CCL11) OT3BIFPK CCL11_HUMAN Decreases Expression [122]
C-C chemokine receptor type 3 (CCR3) OT6GBUFA CCR3_HUMAN Decreases Expression [122]
LIM domain kinase 1 (LIMK1) OTFZ8MZ0 LIMK1_HUMAN Increases Expression [103]
Interleukin-2 (IL2) OTGI4NSA IL2_HUMAN Decreases Expression [119]
Neutrophil gelatinase-associated lipocalin (LCN2) OTSB42BR NGAL_HUMAN Increases Expression [121]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [125]
Lethal(2) giant larvae protein homolog 1 (LLGL1) OTAIQSXZ L2GL1_HUMAN Increases Expression [103]
Calcineurin subunit B type 1 (PPP3R1) OTGQNFJQ CANB1_HUMAN Increases ADR [28]
Catalase (CAT) OTHEBX9R CATA_HUMAN Decreases Response To Substance [128]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Response To Substance [128]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Affects Response To Substance [111]
Cytochrome P450 3A7 (CYP3A7) OTTCDHHM CP3A7_HUMAN Decreases Methylation [110]
------------------------------------------------------------------------------------
⏷ Show the Full List of 49 DOT(s)

References

1 ClinicalTrials.gov (NCT05252754) Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
2 Indomethacin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 ClinicalTrials.gov (NCT04344457) Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19. U.S. National Institutes of Health.
5 Tacrolimus FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6784).
7 In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes. Biopharm Drug Dispos. 2005 Jan;26(1):35-9.
8 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
9 Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther. 1993 Jan;264(1):475-9.
10 Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
11 Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia. 2007 Mar;9(3):222-35.
12 Activation of phospholipase A2 is involved in indomethacin-induced damage in Caco-2 cells. Toxicol In Vitro. 2009 Aug;23(5):887-96.
13 Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
14 Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol. 2005 Jan 21;11(3):340-3. doi: 10.3748/wjg.v11.i3.340.
15 Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 2007 Apr 1;67(7):3185-91. doi: 10.1158/0008-5472.CAN-06-3431.
16 Highly variable pH effects on the interaction of diclofenac and indomethacin with human UDP-glucuronosyltransferases. Toxicol In Vitro. 2012 Dec;26(8):1286-93. doi: 10.1016/j.tiv.2012.01.005. Epub 2012 Jan 14.
17 Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem. 2004 Jul 2;279(27):28320-9. doi: 10.1074/jbc.M401396200. Epub 2004 Apr 26.
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
19 Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
22 Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
23 Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
24 Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils. J Biol Chem. 2002 Jul 19;277(29):26012-20. doi: 10.1074/jbc.M201803200. Epub 2002 Apr 29.
25 The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
26 Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin. Int J Oncol. 2008 Apr;32(4):931-6.
27 Development of an alternative zebrafish model for drug-induced intestinal toxicity. J Appl Toxicol. 2018 Feb;38(2):259-273. doi: 10.1002/jat.3520. Epub 2017 Oct 13.
28 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
29 Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. Biol Reprod. 1999 Jul;61(1):40-5.
30 Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action. Int J Clin Pharmacol Ther. 2001 Jun;39(6):265-70.
31 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
32 Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact. 2003 Feb 1;143-144:503-13.
33 Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol. 2005 May;95(1-5):129-36.
34 Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther. 2005 Dec;315(3):1298-305.
35 Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J. 2006 Feb 15;394(Pt 1):317-24.
36 Indomethacin stimulates activity and expression of ecto-5'-nucleotidase/CD73 in glioma cell lines. Eur J Pharmacol. 2007 Aug 13;569(1-2):8-15.
37 An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol. 2008 Jan 15;75(2):484-93.
38 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
39 Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways. Biomed Res Int. 2013;2013:237543.
40 Human prostaglandin reductase 1 (PGR1): Substrate specificity, inhibitor analysis and site-directed mutagenesis. Chem Biol Interact. 2015 Jun 5;234:105-13.
41 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
42 [Indomethacin induces apoptosis through inhibition of survivin regulated by beta-catenin/TCF4 in human colorectal cancer cells]. Ai Zheng. 2004 Jul;23(7):737-41.
43 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
44 Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
45 Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene. 2001 Nov 29;20(55):7965-75. doi: 10.1038/sj.onc.1204985.
46 Multidrug resistance protein-6 (MRP6) in human dermal fibroblasts. Comparison between cells from normal subjects and from Pseudoxanthoma elasticum patients. Matrix Biol. 2003 Nov;22(6):491-500. doi: 10.1016/j.matbio.2003.09.001.
47 Effect of indomethacin on Bfl-1, WISP-1 and proliferating cell nuclear antigen in colon cancer cell line HCT116 cells. Chin J Dig Dis. 2006;7(4):219-24. doi: 10.1111/j.1443-9573.2006.00272.x.
48 Acute renal effects of sulindac and indomethacin in chronic renal failure. Clin Pharmacol Ther. 1985 Apr;37(4):447-52. doi: 10.1038/clpt.1985.69.
49 Role of endogenous angiotensin II and prostaglandins in the antihypertensive mechanism of angiotensin converting enzyme inhibitor in hypertension. Clin Exp Hypertens A. 1987;9(2-3):569-74. doi: 10.3109/10641968709164225.
50 Matrix metalloproteinase (MMP)-2 and MMP-9 and their inhibitor, TIMP-1, in human term decidua and fetal membranes: the effect of prostaglandin F(2alpha) and indomethacin. Mol Hum Reprod. 2001 Dec;7(12):1187-93. doi: 10.1093/molehr/7.12.1187.
51 Effects of capsaicin, bradykinin and prostaglandin E2 in the human skin. Br J Dermatol. 1992 Feb;126(2):111-7. doi: 10.1111/j.1365-2133.1992.tb07806.x.
52 Differential apoptosis by indomethacin in gastric epithelial cells through the constitutive expression of wild-type p53 and/or up-regulation of c-myc. Biochem Pharmacol. 1999 Jul 1;58(1):193-200. doi: 10.1016/s0006-2952(99)00058-1.
53 Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. Eur J Pharmacol. 1999 May 21;372(3):311-8. doi: 10.1016/s0014-2999(99)00246-0.
54 Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus. Acta Paediatr. 1992 Sep;81(9):672-5. doi: 10.1111/j.1651-2227.1992.tb12330.x.
55 Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. Pediatr Nephrol. 2005 Nov;20(11):1552-6. doi: 10.1007/s00467-005-2022-6. Epub 2005 Aug 17.
56 Indomethacin decreases insulin secretion in patients with type 2 diabetes mellitus. Metabolism. 2000 Jul;49(7):839-44. doi: 10.1053/meta.2000.6748.
57 A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001 Nov 8;414(6860):212-6. doi: 10.1038/35102591.
58 In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. Cytokine. 2004 May 7;26(3):95-101. doi: 10.1016/j.cyto.2003.08.014.
59 An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells. 1995 Aug;13 Suppl 2:28-34.
60 Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology. 2000 Mar;118(3):507-14. doi: 10.1016/s0016-5085(00)70256-3.
61 Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 1999 Dec;360(6):683-90. doi: 10.1007/s002109900145.
62 Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. Neurochem Res. 2000 Nov;25(11):1509-15. doi: 10.1023/a:1007684311023.
63 Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol. 2008 Nov;74(5):1399-406. doi: 10.1124/mol.108.049569. Epub 2008 Aug 4.
64 Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis. 2001 Sep;22(9):1393-7. doi: 10.1093/carcin/22.9.1393.
65 Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet. 2005 Dec 1;14(23):3673-84. doi: 10.1093/hmg/ddi395. Epub 2005 Oct 20.
66 Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk Res. 2000 May;24(5):385-92. doi: 10.1016/s0145-2126(99)00198-8.
67 The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells. Exp Cell Res. 2005 Jan 15;302(2):244-52. doi: 10.1016/j.yexcr.2004.09.021.
68 Indomethacin and ibuprofen induce Hsc70 nuclear localization and activation of the heat shock response in HeLa cells. Biochem Biophys Res Commun. 2004 Jan 23;313(4):863-70. doi: 10.1016/j.bbrc.2003.12.018.
69 Effect of indomethacin on cell cycle proteins in colon cancer cell lines. World J Gastroenterol. 2005 Mar 21;11(11):1693-6. doi: 10.3748/wjg.v11.i11.1693.
70 Effect of indomethacin on E-cadherin and beta-catenin expression in HT-29 colon cancer cells. Exp Mol Pathol. 2006 Feb;80(1):91-6. doi: 10.1016/j.yexmp.2005.04.008. Epub 2005 Jun 16.
71 Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
72 Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands. J Pharmacol Exp Ther. 2004 Nov;311(2):467-75. doi: 10.1124/jpet.104.068254. Epub 2004 Jul 23.
73 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.
74 Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression. Neoplasia. 2002 Sep-Oct;4(5):409-16. doi: 10.1038/sj.neo.7900252.
75 Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol. 2005 Feb;67(2):356-64. doi: 10.1124/mol.104.005108. Epub 2004 Oct 27.
76 Indomethacin and ibuprofen effect on IL-1ra production by mononuclear cells of preterm newborns and adults. Biol Neonate. 2002 Aug;82(2):73-7. doi: 10.1159/000063090.
77 Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. Biol Pharm Bull. 2000 Jul;23(7):815-9. doi: 10.1248/bpb.23.815.
78 Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
79 Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology. 2009 Apr 28;258(2-3):148-56. doi: 10.1016/j.tox.2009.01.016. Epub 2009 Jan 22.
80 Thioredoxin-1 attenuates indomethacin-induced gastric mucosal injury in mice. Free Radic Res. 2007 Aug;41(8):861-9. doi: 10.1080/10715760701199618.
81 Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis. 2002 Jan;23(1):107-14. doi: 10.1093/carcin/23.1.107.
82 Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum. 2002 Dec;46(12):3159-67. doi: 10.1002/art.10692.
83 [Proliferation-inhibiting effect of indomethacin on chronic myeliod leukemia cells is related to the supression of STAT signal transduction pathway]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Dec;12(6):761-5.
84 Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells. Biochem Biophys Res Commun. 2007 Aug 3;359(3):568-73. doi: 10.1016/j.bbrc.2007.05.145. Epub 2007 May 30.
85 [Indomethacin-induced HL-60 leukemic cell apoptosis and the activation of C-jun NH2- terminal kinase signal transduction pathway]. Hunan Yi Ke Da Xue Xue Bao. 2003 Dec;28(6):557-62.
86 Redox-sensitive interaction between KIAA0132 and Nrf2 mediates indomethacin-induced expression of gamma-glutamylcysteine synthetase. Free Radic Biol Med. 2002 Apr 1;32(7):650-62. doi: 10.1016/s0891-5849(02)00755-4.
87 Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol. 2007 Jun 1;563(1-3):49-60. doi: 10.1016/j.ejphar.2007.01.071. Epub 2007 Feb 8.
88 Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells. Br J Cancer. 2005 Apr 25;92(8):1459-66. doi: 10.1038/sj.bjc.6602516.
89 Selective nonsteroidal anti-inflammatory drugs induce thymosin beta-4 and alter actin cytoskeletal organization in human colorectal cancer cells. J Pharmacol Exp Ther. 2004 Dec;311(3):885-91. doi: 10.1124/jpet.104.070664. Epub 2004 Aug 3.
90 Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia. 2000 Jul-Aug;2(4):346-56. doi: 10.1038/sj.neo.7900097.
91 Enhanced protein denaturation in indomethacin-treated cells. Cell Stress Chaperones. 2000 Jan;5(1):8-13. doi: 10.1043/1355-8145(2000)005<0008:EPDIIT>2.0.CO;2.
92 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
93 Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog. 2009 Oct;48(10):942-52. doi: 10.1002/mc.20546.
94 The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene. 2008 Apr 17;27(18):2648-55. doi: 10.1038/sj.onc.1210891. Epub 2007 Dec 3.
95 Indomethacin delays gastric restitution: association with the inhibition of focal adhesion kinase and tensin phosphorylation and reduced actin stress fibers. Exp Biol Med (Maywood). 2002 Jun;227(6):412-24. doi: 10.1177/153537020222700607.
96 Polyphenols protect the epithelial barrier function of Caco-2 cells exposed to indomethacin through the modulation of occludin and zonula occludens-1 expression. J Agric Food Chem. 2013 Jun 5;61(22):5291-7. doi: 10.1021/jf400150p. Epub 2013 May 23.
97 Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
98 Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
99 In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol. 2012 Aug 20;25(8):1616-32. doi: 10.1021/tx300091x. Epub 2012 May 31.
100 Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol. 2002 Feb 1;168(3):981-5. doi: 10.4049/jimmunol.168.3.981.
101 Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology. 2006 Oct;44(4):976-82. doi: 10.1002/hep.21326.
102 GSK3, snail, and adhesion molecule regulation by cyclosporine A in renal tubular cells. Toxicol Sci. 2012 Jun;127(2):425-37. doi: 10.1093/toxsci/kfs108. Epub 2012 Mar 12.
103 Calcineurin is an important factor involved in glucose uptake in human adipocytes. Mol Cell Biochem. 2018 Aug;445(1-2):157-168. doi: 10.1007/s11010-017-3261-0. Epub 2018 Jan 27.
104 Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
105 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
106 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
107 Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
108 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
109 High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
110 Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005 Aug;51(8):1374-81.
111 Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor- are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenet Genomics. 2013 Dec;23(12):649-57. doi: 10.1097/FPC.0000000000000001.
112 Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 2002 Aug 27;74(4):571-2. doi: 10.1097/00007890-200208270-00024.
113 Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
114 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
115 Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant. 2011 Feb;17(2):205-13. doi: 10.1016/j.bbmt.2010.08.014. Epub 2010 Aug 22.
116 CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
117 Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. Am J Transplant. 2007 Apr;7(4):1021-6. doi: 10.1111/j.1600-6143.2006.01728.x.
118 FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol. 2005 Oct;153(4):725-32. doi: 10.1111/j.1365-2133.2005.06779.x.
119 Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol. 2001 Jun;1(6):1219-26. doi: 10.1016/s1567-5769(01)00059-5.
120 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
121 Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Arch Toxicol. 2018 Apr;92(4):1539-1550. doi: 10.1007/s00204-018-2158-3. Epub 2018 Jan 23.
122 Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol. 2005 Jun;152(6):1173-81. doi: 10.1111/j.1365-2133.2005.06474.x.
123 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
124 Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004 Jul;114(1):137-43. doi: 10.1016/j.jaci.2004.03.021.
125 Immunosuppressive calcineurin inhibitor cyclosporine A?induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022 Mar;298(3):101589. doi: 10.1016/j.jbc.2022.101589. Epub 2022 Jan 14.
126 Multicenter prospective investigation on cardiovascular adverse effects of tacrolimus in kidney transplantations. Cardiovasc Drugs Ther. 2003 Mar;17(2):141-9. doi: 10.1023/a:1025339819051.
127 Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol. 2001 Nov;108(5):839-46. doi: 10.1067/mai.2001.118796.
128 Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney Int. 2004 Jan;65(1):139-47. doi: 10.1111/j.1523-1755.2004.00380.x.